Akums Drugs and Pharmaceuticals announces robust Q3 FY 25 results with 12% Adj EBITDA and 15% Adj PAT growth
New Delhi, February 8, 2025: Akums Drugs and Pharmaceuticals Ltd., has announced its consolidated financial results for the quarter ended December 31, 2024, delivering 12% increase in Adjusted EBITDA on year-on-year basis.Key Highlights:For Q3, Operating performance of the company was robust with overall Adj EBITDA growing 12% YoY and Adj PAT growing 15% YoY driven by better profitability in our core CDMO segment. The EBITDA improvement shows our continued improvement in the product mix. API EBITDA losses reduced significantly in Q3 YoY, although prices of cephalosporin APIs still remain low. Additionally, branded formulation business continues to perform well across domestic and export markets.Sanjeev Jain, Managing Director, also shared his views, stating, “Q3 was an exciting quarter for...









